Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect? — Positive
RAPT Zacks Investment Research — July 15, 2025The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Astrana Health, Inc. (ASTH) Could Surge 97.29%: Read This Before Placing a Bet — Positive
ASTH Zacks Investment Research — July 15, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in Astrana Health, Inc. (ASTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Hillman Solutions Corp. (HLMN) Could Rally 40.8%: Here's is How to Trade — Positive
HLMN Zacks Investment Research — July 15, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 40.8% in Hillman Solutions Corp. (HLMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect? — Positive
HRMY Zacks Investment Research — July 15, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect? — Positive
LENZ Zacks Investment Research — July 15, 2025The consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 40.78% Upside in Navigator Holdings (NVGS): Here's What You Should Know — Positive
NVGS Zacks Investment Research — July 15, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 40.8% in Navigator Holdings (NVGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? — Positive
SPRY Zacks Investment Research — July 15, 2025The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Subscribers to Chart of the Week received this commentary on Sunday, July 13.

Apple's latest message to Trump: We're buying American magnets — Positive
AAPL Business Insider — July 15, 2025Apple is investing $500 million in MP Materials, a US producer of rare earth magnets. News of the deal sent MP Materials' stock price soaring more than 25% Tuesday.

Is Quanta Well-Positioned Amid IRA and Domestic Manufacturing Push? — Positive
PWR Zacks Investment Research — July 15, 2025PWR hits $35.3 billion backlog as utility investment, grid upgrades and data center demand drive infrastructure growth.

Should GE Aerospace Stock be in Your Portfolio Pre-Q2 Earnings? — Positive
GE Zacks Investment Research — July 15, 2025GE stock soars 43.8% in three months as Q2 earnings approach, fueled by engine demand and defense strength.

AEVA's Sandia Deal is Big, but Can it Justify the Stock Surge? — Positive
AEVA Zacks Investment Research — July 15, 2025Aeva Technologies expands into security and infrastructure with Sandia Labs, as its soaring stock tests valuation limits.

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? — Positive
NVS Zacks Investment Research — July 15, 2025Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.

Here's Why Cheesecake Factory (CAKE) is a Strong Momentum Stock — Positive
CAKE Zacks Investment Research — July 15, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Federated Hermes (FHI) is a Top Momentum Stock for the Long-Term — Positive
FHI Zacks Investment Research — July 15, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why F.N.B. (FNB) is a Top Momentum Stock for the Long-Term — Positive
FNB Zacks Investment Research — July 15, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Alphabet (GOOGL) is a Top Momentum Stock for the Long-Term — Positive
GOOG GOOGL Zacks Investment Research — July 15, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Paypal (PYPL) is a Strong Momentum Stock — Positive
PYPL Zacks Investment Research — July 15, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Copa Holdings (CPA) is a Top Momentum Stock for the Long-Term — Positive
CPA Zacks Investment Research — July 15, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Yum Brands (YUM) is a Strong Momentum Stock — Positive
YUM Zacks Investment Research — July 15, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
